Free Trial
NASDAQ:DYN

Dyne Therapeutics Q2 2023 Earnings Report

Dyne Therapeutics logo
$8.64 -0.16 (-1.82%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$8.70 +0.06 (+0.69%)
As of 07/11/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics EPS Results

Actual EPS
-$1.08
Consensus EPS
-$0.81
Beat/Miss
Missed by -$0.27
One Year Ago EPS
N/A

Dyne Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dyne Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 3, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Dyne Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Dyne Therapeutics Earnings Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Dyne Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dyne Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your email.

About Dyne Therapeutics

Dyne Therapeutics (NASDAQ:DYN) is a clinical-stage biotechnology company focused on the development of precision genetic therapies for serious rare neuromuscular diseases. Established in 2019 as a spin-out from Flagship Pioneering, Dyne leverages proprietary delivery technology to enhance the uptake and targeting of oligonucleotide therapeutics. The company’s mission is to create potentially transformative treatments for patients affected by diseases such as Duchenne muscular dystrophy, myotonic dystrophy type 1, and limb-girdle muscular dystrophies, which historically have had limited therapeutic options.

At the core of Dyne’s strategy is its FORCE (Facilitated Oligonucleotide Chemistries and Enhanced Delivery) platform, designed to improve cellular delivery of oligonucleotides across muscle and other challenging tissues. This platform enables the company to optimize stability, tissue specificity, and pharmacological activity of its candidates. Dyne’s lead program, DYST-ON, is a next-generation antisense oligonucleotide for Duchenne muscular dystrophy currently in clinical development, while MYO-101 for myotonic dystrophy type 1 and additional programs targeting various limb-girdle muscular dystrophy subtypes are advancing in preclinical and early clinical stages.

Dyne maintains collaborations with several major pharmaceutical and biotechnology partners to broaden its research capabilities and accelerate clinical development. The company has entered strategic alliances aimed at co-developing next-generation oligonucleotide drugs, drawing upon the global expertise of industry leaders. These partnerships are intended to leverage shared resources for manufacturing, regulatory planning, and commercialization, positioning Dyne to bring potential therapies to patients more efficiently.

Headquartered in Cambridge, Massachusetts, Dyne Therapeutics serves both U.S. and international patient communities through ongoing clinical trials and research activities. Under the leadership of Founder and Chief Executive Officer Edward Kaye, Ph.D., the management team combines deep expertise in molecular biology, drug delivery, and rare disease clinical development. With a commitment to scientific innovation and patient-centric research, Dyne is advancing a pipeline of differentiated therapies that aim to address unmet needs in neuromuscular disease treatment.

View Dyne Therapeutics Profile

More Earnings Resources from MarketBeat